Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’s Peanut Allergy Setback Perks Up Rivals

Executive Summary

Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.

You may also be interested in...



Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire

Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.

DBV Pulls EU Peanut Allergy Patch Filing To Work On A Stronger Application

Following regulatory setbacks in the US and also now in the EU, DBV Technologies is to conduct a new pivotal trial of a modified version of its peanut allergy patch to support its efforts to win marketing approval.

Novartis’s Ligelizumab Founders In Phase III Despite Positive Predictions

Novartis’s ligelizumab failed to show superiority over standard of care Xolair, subverting hopeful analyst expectations and changing the firm’s focus in chronic spontaneous urticaria to a BTK inhibitor asset.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel